Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- U.S. - Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45.
From Zimmer Biomet Holdings, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- U.S. business grew 3.2% in Q1 2026; international grew 2.5%.
- Overall organic constant currency revenue growth guidance for 2026 maintained at 1% to 3%.
- Growth expected to be roughly consistent throughout 2026.
- Paragon 28 acquisition to contribute ~100 basis points to reported sales growth in 2026.
- Technology and data, bone cement, surgical business grew nearly 12% in Q1 driving growth.
- Knee market: U.S. knees grew 2.2% with strong partial knee sales; hips grew 5% in the U.S.
- International markets expected mid-single digit growth in second half of 2026.
- Monogram robotic system launch anticipated in early 2027 expected to drive future growth.
- Sales force transformation enhancing productivity and specialty focus to support growth.
2 more points from Zimmer Biomet Holdings, Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zimmer Biomet Holdings, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Zimmer Biomet is investing heavily in innovation and go-to-market transformation, including technology launches like Monogram (expected early 2027) and expansion of the sales force with over 200 new reps specifically for Monogram.
- The company is expanding its manufacturing footprint into lower-cost geographies to improve operational efficiency and margins.
- There is a sizable investment focus on building clinical evidence, economic strategy, and new customer targeting strategies to drive adoption of new products.
- Zimmer Biomet committed as the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund focusing on breakthrough technologies such as AI, data applications, and cartilage repair.
2 more points from Zimmer Biomet Holdings, Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Zimmer Biomet Holdings, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Zimmer Biomet Holdings, Inc.'s call on order book
Create a free account to keep reading this call
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zimmer Biomet Holdings, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zimmer Biomet Holdings, Inc. Q2 FY26 results?
- U.S. - Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45.
What is Zimmer Biomet Holdings, Inc. share price analysis?
Zimmer Biomet Holdings, Inc. currently shows a neutral. The stock trades at a P/E of 21.9 with a market cap of $16,023. Investors should review the full earnings analysis for detailed insights.
Is Zimmer Biomet Holdings, Inc. planning capital expenditure?
- Zimmer Biomet is investing heavily in innovation and go-to-market transformation, including technology launches like Monogram (expected early 2027) and expansion of the sales force with over 200 new reps specifically for Monogram. - The company is expanding its manufacturing footprint into lower-cost geographies to improve operational efficiency and margins. - There is a sizable investment focus on building clinical evidence, economic strategy, and new customer targeting strategies to drive adoption of new products. - Zimmer Biomet committed as the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund focusing on breakthrough technologies such as AI, data applications, and cartilage repair. - Hiring Dr.
Keep Zimmer Biomet Holdings, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.